Ferlatum Fol, 15 ml 10 pcs

According to the instructions to Furlatum, this drug has a pronounced anti-anemic effect. The active ingredient of the drug is iron succinylate protein. This substance is a complex compound in which trivalent iron atoms are arranged in the environment of a semi-synthetic protein carrier, which does not cause irritation and damage to the mucosa of the gastrointestinal tract.

The main function of iron is to deliver oxygen to all body tissues. It is part of hemoglobin, myoglobin, iron-containing enzymes-cytochorms, catalyzes oxidative reactions, is responsible for electron transport, hydroxylation and other metabolic processes.

Ferlatum analogues include such drugs as Ferlatum Fol and Iron Protein Succinylate.

Indications

Bleeding, Anemia, Hypovitaminosis, Pale skin, Weakness and fatigue, Prevention of iron deficiency

According to the instructions Furlatum and analogues Furlatum are prescribed in the following cases:

• treatment of clinically expressed iron deficiency (iron deficiency anemia);
• prevention of iron deficiency during pregnancy and during the lactation period, during active growth of the body, in cases of prolonged bleeding, as well as in unbalanced and incomplete nutrition.

.

Active ingredient

Iron proteinsuccinylate

Composition

1 bottle of oral solution contains:

Active substance:

The iron protein succinylate 800 mg, which corresponds to Fe 3+ 40 mg.

Associates:

sorbitol,

propylene glycol,

sodium methyl parahydroxybenzoate,

propyl parahydroxybenzoate,

Cherry flavoring (concentrated wild black cherry flavoring, vanillin, amyl acetate, small amounts of other esters, benzaldehyde, clove bud oil, propylene glycol, diethylene glycol monoethyl ether, water),

sodium saccharinate,

purified water.

How to take, the dosage

The drug Furlatum is intended for internal use before or after meals.

In adults, analogues of Furlatum and the drug itself are prescribed 15-30 ml per day, divided into 2 doses. For children, the daily dosage of the drug is determined according to the following scheme: 1.5 ml of the solution for each kilogram of weight. The resulting dose is also divided into two doses. Pregnant and lactating women take Firlatum 15 ml per day.

After the parameters of hemoglobin and serum iron in the patient’s body are normalized, it is recommended to continue taking the drug for another 2-3 months. The total duration of therapy with Firlatum should not exceed six months, except for pregnancy and cases associated with intense prolonged blood loss (hemorrhoids, menorrhagia).

Interaction

No interaction of the drug Furlatum Fol with other medicinal products was noted during concomitant use.

Iron absorption may be increased when concomitant use of the drug Furlathum Fol with ascorbic acid at a dose of >200 mg.

Iron absorption may be decreased when concomitant use of the drug Ferlatum Fol with antacids.

Chloramphenicol causes a delayed response to iron therapy.

Pharmacological interaction in concomitant use of the drug Forlatum Fol with histamine H2-receptor antagonists is absent.

Particular anticancer and anti leukemic drugs (including aminopterin, methotrexate and other pterine derivatives) show the properties of folate antagonists.

Special Instructions

The continuous period of use of the drug Furlatum Fol should not exceed 6 months, except in cases of chronic blood loss (including menorrhagia, hemorrhoids) and pregnancy.

Due to possible allergic reactions the drug should be used with caution in patients with intolerance of milk protein.

Ferlatum Fol contains sorbitol, so the drug should not be used in patients with hereditary fructose intolerance.

Contraindications

The drug itself and analogues of Furlathum should not be taken if patients have the following ailments:

• non-iron deficiency anemia (hemolytic or megaloblastic);
• chronic pancreatitis;
• impaired iron utilization (lead or sideroachrestic anemia);
• hepatic cirrhosis;
• hypersensitivity to the ingredients of the drug;
• hemochromatosis.

.

Side effects

In their reviews of Furlatum, some patients note that the drug may provoke the following adverse reactions from the digestive system: nausea, pain in the epigastric region, diarrhea or constipation.

These conditions most commonly develop when using the solution in higher dosages.

In general, once the drug is discontinued or the dosage is reduced, the above symptoms disappear.

Overdose

Overdose of this drug is accompanied by the following symptoms: nausea and vomiting, pain in the epigastrium, diarrhea in the first 8 hours after taking the drug. In some cases there may be pale skin, drowsiness, development of shock and coma.

In case of overdose with Firlatum and its analogues it is necessary to perform urgent gastric lavage and provide the patient with symptomatic treatment.

Pregnancy use

The use of the drug Ferlatum Fol is especially recommended for the prevention and treatment of iron and folate deficiency that develops during pregnancy and during breastfeeding.

Similarities

Ferlatum